Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that beat revenue expectations and prompted raised full-year guidance. JNJ leaned on a ...

Rinvoq is the first oral drug for moderate to severe Crohn’s disease — a chronic intestinal disorder — to be approved by the Food and Drug Administration. There is no cure for Crohn’s disease, and the ...

AbbVie’s ABBV immunology franchise remained the company’s biggest growth driver in the first quarter of 2026, which beat expectations for both earnings and sales. The stronger-than-expected sales of ...

Rinvoq (upadacitinib) is a brand-name tablet that’s prescribed for rheumatoid arthritis and certain other conditions. The cost of the drug with and without insurance can depend on several factors, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Rinvoq (upadacitinib) is a brand-name tablet that’s prescribed for rheumatoid arthritis and certain other conditions. The cost of the drug with and without insurance can depend on several factors, ...

Doctors prescribe Rinvoq (upadacitinib) to treat certain inflammatory conditions, such as rheumatoid arthritis (RA) and ulcerative colitis (UC). It’s available as an extended-release oral tablet and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), a Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who ...

Less than a year ago, AbbVie's star immunology drug Rinvoq picked up its seventh FDA approval when the agency endorsed it in Crohn's disease. After a new positive pivotal trial, the drug could be ...

AbbVie's revenue for the first quarter came in at $15 billion, 12.4% higher than the year-ago period. The company had ...

Rinvoq achieved superiority compared to Dupixent for the trial's primary endpoint, meaning the former drug reported a higher number of patients with at least a 75% improvement in the Eczema Area and ...